CKAP4 is a potential therapeutic target to overcome resistance to EGFR-TKIs in lung adenocarcinoma
Genes & Genomics · 2025
DOI: 10.1007/s13258-024-01606-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes & Genomics, 2025. Verfasst von Seongeun Song und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Adenocarcinoma of Lung, Protein Kinase Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Korea Institute for Advanced Study.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea.
- Department of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea. Sangmyung.rhee@cau.ac.kr.
Förderung
- Korea Institute for Advanced Study
Zitieren
APA
Song, S., & Rhee, S. (2025). CKAP4 is a potential therapeutic target to overcome resistance to EGFR-TKIs in lung adenocarcinoma. Genes & Genomics. https://doi.org/10.1007/s13258-024-01606-7
Vancouver
Song S, Rhee S. CKAP4 is a potential therapeutic target to overcome resistance to EGFR-TKIs in lung adenocarcinoma. Genes & Genomics. 2025. doi:10.1007/s13258-024-01606-7
BibTeX
@article{Song2025,
author = {Song, Seongeun and Rhee, Sangmyung},
title = {CKAP4 is a potential therapeutic target to overcome resistance to EGFR-TKIs in lung adenocarcinoma},
journal = {Genes & Genomics},
year = {2025},
doi = {10.1007/s13258-024-01606-7}
}
EUVIMED